Literature DB >> 25013093

Questionable research and marketing of a combination drug for smoker's lungs.

Peter Christian Gøtzsche1.   

Abstract

Year:  2014        PMID： 25013093      PMCID： PMC4093763          DOI： 10.1177/0141076814541847

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  7 in total

1.  Prevention of death in COPD.

Authors:  Carlo La Vecchia; Leonardo M Fabbri
Journal:  N Engl J Med       Date:  2007-05-24       Impact factor: 91.245

2.  Prevention of death in COPD.

Authors:  Martin Duerden
Journal:  N Engl J Med       Date:  2007-05-24       Impact factor: 91.245

3.  Prevention of death in COPD.

Authors:  Niall Keaney
Journal:  N Engl J Med       Date:  2007-05-24       Impact factor: 91.245

Review 4.  Methodological issues in therapeutic trials of COPD.

Authors:  S Suissa; P Ernst; K L Vandemheen; S D Aaron
Journal:  Eur Respir J       Date:  2008-01-23       Impact factor: 16.671

5.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease.

Authors:  Peter M A Calverley; Julie A Anderson; Bartolome Celli; Gary T Ferguson; Christine Jenkins; Paul W Jones; Julie C Yates; Jørgen Vestbo
Journal:  N Engl J Med       Date:  2007-02-22       Impact factor: 91.245

6.  The TORCH (towards a revolution in COPD health) survival study protocol.

Authors:  J Vestbo
Journal:  Eur Respir J       Date:  2004-08       Impact factor: 16.671

7.  Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study.

Authors:  Bartolomé R Celli; Nicola E Thomas; Julie A Anderson; Gary T Ferguson; Christine R Jenkins; Paul W Jones; Jørgen Vestbo; Katharine Knobil; Julie C Yates; Peter M A Calverley
Journal:  Am J Respir Crit Care Med       Date:  2008-05-29       Impact factor: 21.405
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.